OncoSec Medical (ONCS) Price Target Lowered to $3.00 at Piper Jaffray Companies

Share on StockTwits

OncoSec Medical (NASDAQ:ONCS) had its target price cut by Piper Jaffray Companies from $5.00 to $3.00 in a research report sent to investors on Tuesday morning, The Fly reports. They currently have an overweight rating on the biotechnology company’s stock.

Other research analysts have also recently issued reports about the company. HC Wainwright set a $4.00 price objective on OncoSec Medical and gave the stock a buy rating in a research report on Tuesday, July 31st. Dawson James reaffirmed a buy rating on shares of OncoSec Medical in a research report on Monday, July 16th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $4.00.

NASDAQ:ONCS opened at $0.97 on Tuesday. OncoSec Medical has a 1 year low of $0.68 and a 1 year high of $2.95. The stock has a market capitalization of $111.32 million, a price-to-earnings ratio of -0.93 and a beta of 2.28.

Several hedge funds have recently bought and sold shares of the company. Nexthera Capital LP raised its holdings in OncoSec Medical by 26.6% during the second quarter. Nexthera Capital LP now owns 2,614,297 shares of the biotechnology company’s stock worth $3,608,000 after acquiring an additional 550,000 shares in the last quarter. Millennium Management LLC raised its holdings in OncoSec Medical by 19.5% during the second quarter. Millennium Management LLC now owns 1,195,315 shares of the biotechnology company’s stock worth $1,650,000 after acquiring an additional 194,739 shares in the last quarter. 683 Capital Management LLC bought a new stake in OncoSec Medical during the second quarter worth about $414,000. BlackRock Inc. raised its holdings in OncoSec Medical by 1,303.5% during the second quarter. BlackRock Inc. now owns 238,940 shares of the biotechnology company’s stock worth $330,000 after acquiring an additional 221,916 shares in the last quarter. Finally, DRW Securities LLC raised its holdings in OncoSec Medical by 157.1% during the second quarter. DRW Securities LLC now owns 180,000 shares of the biotechnology company’s stock worth $248,000 after acquiring an additional 110,000 shares in the last quarter. 23.13% of the stock is owned by institutional investors.

OncoSec Medical Company Profile

OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer.

Read More: How is the S&P 500 index different from the DJIA?

The Fly

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply